CORE OLE-TIMI 72c is an open label extension of 885 patients from the CORE (TIMI 72a) & CORE2 CS6-TIMI 72b trials, continuing on 80 mg Q4W of Olezarsen for a planned duration of ≥ 2 years.
An Academic Research Organization of Brigham & Women's Hospital and An Affiliate of Harvard Medical School